Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

β-Sheet Breakers for Alzheimers Disease Therapy

Author(s): Bieler S. and Soto C.

Volume 5, Issue 6, 2004

Page: [553 - 558] Pages: 6

DOI: 10.2174/1389450043345290

Price: $65

Abstract

A growing wealth of evidence indicates that the key pathological event in Alzheimers disease is the conversion of the normal soluble amyloid-β peptide into β-sheet-rich oligomeric structures which have a neurotoxic activity and ability to form insoluble amyloid deposits that accumulate in the brain. b-sheet breakers constitute a new class of drugs that are designed to specifically bind amyloid-β peptide and block and / or reverse this abnormal conformational change. In this article we review this approach, describe diverse compounds reported to have this activity and summarize the data supporting the view that b-sheet breakers could be serious candidates to combat this devastating disease.

Keywords: alzheimer disease, amyloid, therapy


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy